Humana Q4 2020 Earnings Report
Key Takeaways
Humana reported a loss per common share of $2.07 on a GAAP basis and $2.30 on an Adjusted basis for Q4 2020. The company's results were impacted by COVID-19 treatment and testing costs, crisis relief efforts, strategic investments, and increased marketing expenses. Humana announced FY 2021 EPS guidance in a range of $20.82 to $21.32 on a GAAP basis, $21.25 to $21.75 on Adjusted basis.
Reported 4Q20 loss per common share of $2.07 on a GAAP basis, $2.30 on an Adjusted basis.
Announced FY 2021 EPS guidance in a range of $20.82 to $21.32 on a GAAP basis, $21.25 to $21.75 on Adjusted basis.
Reaffirmed FY 2021 expected individual Medicare Advantage membership growth range of approximately 425,000 to 475,000 members, representing expected year-over-year growth of approximately 11 to 12 percent.
Experienced a significant increase in COVID-19 admissions in nearly all of the markets in which it operates across its Medicare Advantage, Medicaid, and group commercial insurance business lines.
Humana
Humana
Humana Revenue by Segment
Forward Guidance
Humana provided its GAAP and Adjusted EPS guidance for the year ending December 31, 2021 (FY 2021).